- Home
- BRY vs GNFT Comparison
BRY vs GNFT Comparison
Compare BRY & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRY
- GNFT
- Stock Information
- Founded
- BRY 1909
- GNFT 1999
- Country
- BRY United States
- GNFT France
- Employees
- BRY N/A
- GNFT N/A
- Industry
- BRY Oil & Gas Production
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRY Energy
- GNFT Health Care
- Exchange
- BRY Nasdaq
- GNFT Nasdaq
- Market Cap
- BRY 186.1M
- GNFT 186.3M
- IPO Year
- BRY N/A
- GNFT 2019
- Fundamental
- Price
- BRY $3.00
- GNFT $4.14
- Analyst Decision
- BRY Buy
- GNFT Strong Buy
- Analyst Count
- BRY 2
- GNFT 1
- Target Price
- BRY $4.00
- GNFT $13.00
- AVG Volume (30 Days)
- BRY 935.9K
- GNFT 4.0K
- Earning Date
- BRY 08-06-2025
- GNFT 09-18-2025
- Dividend Yield
- BRY 4.00%
- GNFT N/A
- EPS Growth
- BRY N/A
- GNFT N/A
- EPS
- BRY N/A
- GNFT 0.03
- Revenue
- BRY $753,737,000.00
- GNFT $73,187,701.00
- Revenue This Year
- BRY N/A
- GNFT $15.98
- Revenue Next Year
- BRY $1.01
- GNFT N/A
- P/E Ratio
- BRY N/A
- GNFT $132.83
- Revenue Growth
- BRY N/A
- GNFT 105.01
- 52 Week Low
- BRY $2.11
- GNFT $2.55
- 52 Week High
- BRY $6.95
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- BRY 48.06
- GNFT 58.36
- Support Level
- BRY $3.03
- GNFT $3.94
- Resistance Level
- BRY $3.23
- GNFT $4.20
- Average True Range (ATR)
- BRY 0.16
- GNFT 0.13
- MACD
- BRY -0.02
- GNFT 0.05
- Stochastic Oscillator
- BRY 8.11
- GNFT 91.62
About BRY Berry Corporation (bry)
Berry Corp (bry) is a western United States independent upstream energy company with a focus on the conventional, long-lived oil reserves in the San Joaquin basin of California. Its operating segments includes Exploration and Production (E&P) and Well Servicing and Abandonment. The company generates maximum revenue from the Exploration and Production (E&P) segment.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.